{
  "denotations": [
    {
      "id": "T3",
      "obj": "Disease",
      "span": {
        "begin": 39,
        "end": 53
      }
    },
    {
      "id": "T5",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 73,
        "end": 76
      }
    },
    {
      "id": "T6",
      "obj": "Chemical",
      "span": {
        "begin": 153,
        "end": 165
      }
    },
    {
      "id": "T7",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 138,
        "end": 142
      }
    },
    {
      "id": "T1",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 0,
        "end": 4
      }
    },
    {
      "id": "T8",
      "obj": "Chemical",
      "span": {
        "begin": 73,
        "end": 86
      }
    },
    {
      "id": "T9",
      "obj": "Chemical",
      "span": {
        "begin": 87,
        "end": 94
      }
    },
    {
      "id": "T11",
      "obj": "Chemical",
      "span": {
        "begin": 138,
        "end": 152
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "21351275_1",
  "text": "BRAF mutation -selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus ."
}
